Drug Profile
Elgemtumab - MorphoSys/Novartis
Alternative Names: LJM-716; NOV-6Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator MorphoSys; Novartis
- Developer Memorial Sloan-Kettering Cancer Center; Novartis Oncology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours
Most Recent Events
- 07 Jul 2021 Memorial Sloan-Kettering Cancer Center completes its phase I trial for Breast cancer (combination therapy, metastatic disease) in USA (NCT02167854)
- 02 Aug 2017 Novartis completes a phase I trial in Breast cancer and Gastric cancer (combination therapy, metastatic disease) in USA, United Kingdom, Belgium, France, Italy, Netherlands, Spain, Taiwan and South Korea (IV) (NCT01602406)
- 27 Jan 2017 Discontinued - Phase-I for Breast cancer (Combination therapy, Metastatic disease) in South Korea, Italy, USA, United Kingdom, Netherlands, Belgium, France, Spain, Taiwan (IV) (Novartis 20-F filed in 2017)